{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:51Z","timestamp":1769170971634,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,21]]},"DOI":"10.7759\/cureus.39309","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T22:01:31Z","timestamp":1684706491000},"source":"Crossref","is-referenced-by-count":5,"title":["Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy"],"prefix":"10.7759","author":[{"given":"Martin","family":"Tarzian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Ndrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srujan","family":"Kaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Beason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adegbenro O","family":"Fakoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20569","article-title":"The severity of psychiatric disorders","volume":"17","author":"Zimmerman M","year":"2018","unstructured":"Zimmerman M, Morgan TA, Stanton K. The severity of psychiatric disorders. World Psychiatry. 2018, 17:258-75. 10.1002\/wps.20569","journal-title":"World Psychiatry"},{"key":"ref2","article-title":"The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020","author":"Murray CL","year":"1996","unstructured":"Murray CL, Lopez AD, Brown P. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. The Harvard School of Public Health, Boston, Massachusetts; 1996."},{"key":"ref3","unstructured":"Depressive disorders \u2014 level 3 cause. (2020). Accessed. April 24, 2023: https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/depressive-disorders-level-3-cause."},{"key":"ref4","unstructured":"Bipolar disorder \u2014 level 3 cause. (2020). Accessed. April 24, 2023: https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/bipolar-disorder-level-3-cause."},{"key":"ref5","unstructured":"Schizophrenia \u2014 level 3 cause. (2020). Accessed. April 24, 2023: https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/schizophrenia-level-3-cause."},{"key":"ref6","unstructured":"Mental disorders. (2022). Accessed. April 24, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072143","article-title":"A history of the pharmacological treatment of bipolar disorder","volume":"19","author":"L\u00f3pez-Mu\u00f1oz F","year":"2018","unstructured":"L\u00f3pez-Mu\u00f1oz F, Shen WW, D'Ocon P, Romero A, \u00c1lamo C. A history of the pharmacological treatment of bipolar disorder. Int J Mol Sci. 2018, 19:2143. 10.3390\/ijms19072143","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20200051","article-title":"Contrasting typical and atypical antipsychotic drugs","volume":"19","author":"Meltzer HY","year":"2021","unstructured":"Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. Focus (Am Psychiatr Publ). 2021, 19:3-13. 10.1176\/appi.focus.20200051","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah A","year":"2005","unstructured":"Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005, 7:268-74. 10.4088\/pcc.v07n0602","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02895-4","article-title":"Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013-2018","volume":"20","author":"Dennis JA","year":"2020","unstructured":"Dennis JA, Gittner LS, Payne JD, Nugent K. Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013-2018. BMC Psychiatry. 2020, 20:483. 10.1186\/s12888-020-02895-4","journal-title":"BMC Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2016.52.2.2461868","article-title":"Cariprazine: new dopamine biased agonist for neuropsychiatric disorders","volume":"52","author":"De Deurwaerd\u00e8re P","year":"2016","unstructured":"De Deurwaerd\u00e8re P. Cariprazine: new dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc). 2016, 52:97-110. 10.1358\/dot.2016.52.2.2461868","journal-title":"Drugs Today (Barc)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0442-z","article-title":"Cariprazine: a review in schizophrenia","volume":"31","author":"Garnock-Jones KP","year":"2017","unstructured":"Garnock-Jones KP. Cariprazine: a review in schizophrenia. CNS Drugs. 2017, 31:513-25. 10.1007\/s40263-017-0442-z","journal-title":"CNS Drugs"},{"key":"ref13","unstructured":"Drugs@FDA data files. (2022). Accessed. April 24, 2023: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drugsfda-data-files."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss B","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, et al.. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010, 333:328-40. 10.1124\/jpet.109.160432","journal-title":"J Pharmacol Exp Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0006-7","article-title":"Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome L","year":"2013","unstructured":"Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013, 30:114-26. 10.1007\/s12325-013-0006-7","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl SM","year":"2016","unstructured":"Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016, 21:123-7. 10.1017\/S1092852916000043","journal-title":"CNS Spectr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff P","year":"2017","unstructured":"Sokoloff P, Le Foll B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017, 45:2-19. 10.1111\/ejn.13390","journal-title":"Eur J Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder CA","year":"2010","unstructured":"Heidbreder CA, Newman AH. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci. 2010, 1187:4-34. 10.1111\/j.1749-6632.2009.05149.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(96)10037-0","article-title":"Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists","volume":"19","author":"Artigas F","year":"1996","unstructured":"Artigas F, Romero L, de Montigny C, et al.. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996, 19:378-83. 10.1016\/S0166-2236(96)10037-0","journal-title":"Trends Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada P","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013, 27:703-16. 10.1007\/s40263-013-0071-0","journal-title":"CNS Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S35137","article-title":"A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia","volume":"9","author":"Caccia S","year":"2013","unstructured":"Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013, 9:319-28. 10.2147\/TCRM.S35137","journal-title":"Ther Clin Risk Manag"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam S","year":"2016","unstructured":"Durgam S, Litman RE, Papadakis K, Li D, N\u00e9meth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016, 31:61-8. 10.1097\/YIC.0000000000000110","journal-title":"Int Clin Psychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1459-z","article-title":"The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis","volume":"17","author":"Nasrallah HA","year":"2017","unstructured":"Nasrallah HA, Earley W, Cutler AJ, et al.. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017, 17:305. 10.1186\/s12888-017-1459-z","journal-title":"BMC Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane JM","year":"2015","unstructured":"Kane JM, Zukin S, Wang Y, et al.. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015, 35:367-73. 10.1097\/JCP.0000000000000346","journal-title":"J Clin Psychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000187","article-title":"Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies","volume":"32","author":"Earley W","year":"2017","unstructured":"Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017, 32:319-28. 10.1097\/YIC.0000000000000187","journal-title":"Int Clin Psychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam S","year":"2014","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014, 152:450-7. 10.1016\/j.schres.2013.11.041","journal-title":"Schizophr Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam S","year":"2015","unstructured":"Durgam S, Cutler AJ, Lu K, et al.. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015, 76:e1574-82. 10.4088\/JCP.15m09997","journal-title":"J Clin Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam S","year":"2016","unstructured":"Durgam S, Earley W, Li R, et al.. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016, 176:264-71. 10.1016\/j.schres.2016.06.030","journal-title":"Schizophr Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4450-3","article-title":"Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study","volume":"234","author":"Durgam S","year":"2017","unstructured":"Durgam S, Greenberg WM, Li D, et al.. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017, 234:199-209. 10.1007\/s00213-016-4450-3","journal-title":"Psychopharmacology (Berl)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000220","article-title":"Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study","volume":"23","author":"Cutler AJ","year":"2018","unstructured":"Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, N\u00e9meth G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018, 23:39-50. 10.1017\/S1092852917000220","journal-title":"CNS Spectr"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam S","year":"2015","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015, 17:63-75. 10.1111\/bdi.12238","journal-title":"Bipolar Disord"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.09.040","article-title":"Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder","volume":"226","author":"Earley W","year":"2018","unstructured":"Earley W, Durgam S, Lu K, Ruth A, N\u00e9meth G, Laszlovszky I, Yatham LN. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018, 226:239-44. 10.1016\/j.jad.2017.09.040","journal-title":"J Affect Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.07.020","article-title":"Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials","volume":"257","author":"McIntyre RS","year":"2019","unstructured":"McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord. 2019, 257:600-6. 10.1016\/j.jad.2019.07.020","journal-title":"J Affect Disord"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12850","article-title":"Cariprazine in the treatment of bipolar disorder: a systematic review and meta-analysis","volume":"22","author":"Pinto JV","year":"2020","unstructured":"Pinto JV, Saraf G, Vigo D, Keramatian K, Chakrabarty T, Yatham LN. Cariprazine in the treatment of bipolar disorder: a systematic review and meta-analysis. Bipolar Disord. 2020, 22:360-71. 10.1111\/bdi.12850","journal-title":"Bipolar Disord"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese JR","year":"2015","unstructured":"Calabrese JR, Keck PE Jr, Starace A, et al.. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015, 76:284-92. 10.4088\/JCP.14m09081","journal-title":"J Clin Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","author":"Yatham LN","year":"2020","unstructured":"Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. Int Clin Psychopharmacol. 2020, 35:147-56. 10.1097\/YIC.0000000000000307","journal-title":"Int Clin Psychopharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam S","year":"2016","unstructured":"Durgam S, Earley W, Lipschitz A, et al.. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016, 173:271-81. 10.1176\/appi.ajp.2015.15020164","journal-title":"Am J Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley WR","year":"2020","unstructured":"Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020, 22:372-84. 10.1111\/bdi.12852","journal-title":"Bipolar Disord"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley W","year":"2019","unstructured":"Earley W, Burgess MV, Rekeda L, et al.. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019, 176:439-48. 10.1176\/appi.ajp.2018.18070824","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919001287","article-title":"Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies","volume":"25","author":"McIntyre RS","year":"2020","unstructured":"McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr. 2020, 25:502-10. 10.1017\/S1092852919001287","journal-title":"CNS Spectr"},{"key":"ref41","unstructured":"Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. (2012). Accessed. April 24, 2023: https:\/\/www.researchgate.net\/publication\/312865325_Cariprazine_exhibits_dopamine_D3_receptor-dependent_antidepressant...."},{"key":"ref42","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam S","year":"2016","unstructured":"Durgam S, Earley W, Guo H, et al.. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016, 77:371-8.","journal-title":"J Clin Psychiatry"},{"key":"ref43","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley WR","year":"2018","unstructured":"Earley WR, Guo H, N\u00e9meth G, Hars\u00e1nyi J, Thase ME. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull. 2018, 48:62-80.","journal-title":"Psychopharmacol Bull"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000246","article-title":"Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder","volume":"34","author":"Vieta E","year":"2019","unstructured":"Vieta E, Earley WR, Burgess MV, et al.. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol. 2019, 34:76-83. 10.1097\/YIC.0000000000000246","journal-title":"Int Clin Psychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava M","year":"2018","unstructured":"Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, N\u00e9meth G. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018, 33:312-21. 10.1097\/YIC.0000000000000235","journal-title":"Int Clin Psychopharmacol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852923001797","article-title":"Adjunctive cariprazine in patients with major depressive disorder: post hoc analysis of efficacy by baseline antidepressant response","volume":"28","author":"Papakostas G","year":"2023","unstructured":"Papakostas G, Yeung P, Chen C, Waraich S, Kerolous M. Adjunctive cariprazine in patients with major depressive disorder: post hoc analysis of efficacy by baseline antidepressant response.  CNS Spectrums. 2023, 28:244-5. 10.1017\/S1092852923001797","journal-title":"CNS Spectrums"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852923001992","article-title":"Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2B and 3 clinical trials","volume":"28","author":"Thase M","year":"2023","unstructured":"Thase M, Yeung P, Hankinson A, Liu M, Rekeda L, Earley WR. Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2B and 3 clinical trials. CNS Spectrums. 2023, 28:255-6. 10.1017\/S1092852923001992","journal-title":"CNS Spectrums"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi K","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, et al.. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019, 34:180-98. 10.1002\/mds.27602","journal-title":"Mov Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/155384-cariprazine-for-treating-schizophrenia-mania-bipolar-depression-and-unipolar-depression-a-review-of-its-efficacy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:55Z","timestamp":1707508915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/155384-cariprazine-for-treating-schizophrenia-mania-bipolar-depression-and-unipolar-depression-a-review-of-its-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,21]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.39309","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,21]]}}}